Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cell Therapeutics, Ortho Biotech Inc., R. W. Johnson Pharmaceuticals Research Institute deal

Cell Therapeutics will collaborate with the two Johnson & Johnson subsidiaries to complete development of lisofylline, an inhibitor of phosphatidic acid,

Read the full 218 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE